- Home
- ORKA vs ANGO Comparison
ORKA vs ANGO Comparison
Compare ORKA & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- ANGO
- Stock Information
- Founded
- ORKA 2004
- ANGO 1988
- Country
- ORKA United States
- ANGO United States
- Employees
- ORKA N/A
- ANGO N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ANGO Medical/Dental Instruments
- Sector
- ORKA Health Care
- ANGO Health Care
- Exchange
- ORKA Nasdaq
- ANGO Nasdaq
- Market Cap
- ORKA 429.4M
- ANGO 439.5M
- IPO Year
- ORKA N/A
- ANGO 2004
- Fundamental
- Price
- ORKA $10.09
- ANGO $9.60
- Analyst Decision
- ORKA Strong Buy
- ANGO Strong Buy
- Analyst Count
- ORKA 7
- ANGO 2
- Target Price
- ORKA $39.67
- ANGO $14.00
- AVG Volume (30 Days)
- ORKA 394.0K
- ANGO 619.3K
- Earning Date
- ORKA 05-15-2025
- ANGO 04-02-2025
- Dividend Yield
- ORKA N/A
- ANGO N/A
- EPS Growth
- ORKA N/A
- ANGO N/A
- EPS
- ORKA N/A
- ANGO N/A
- Revenue
- ORKA N/A
- ANGO $283,320,000.00
- Revenue This Year
- ORKA N/A
- ANGO N/A
- Revenue Next Year
- ORKA N/A
- ANGO $6.35
- P/E Ratio
- ORKA N/A
- ANGO N/A
- Revenue Growth
- ORKA N/A
- ANGO N/A
- 52 Week Low
- ORKA $5.49
- ANGO $5.47
- 52 Week High
- ORKA $53.88
- ANGO $13.50
- Technical
- Relative Strength Index (RSI)
- ORKA N/A
- ANGO 50.63
- Support Level
- ORKA N/A
- ANGO $9.09
- Resistance Level
- ORKA N/A
- ANGO $9.76
- Average True Range (ATR)
- ORKA 0.00
- ANGO 0.50
- MACD
- ORKA 0.00
- ANGO 0.02
- Stochastic Oscillator
- ORKA 0.00
- ANGO 71.67
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.